Checkpoint Inhibitors and Induction of Celiac Disease-like Condition
Immune checkpoint inhibitors herald a new era in oncological therapy-resistant cancer, thus bringing hope for better outcomes and quality of life for patients. However, as with other medications, they are not without serious side effects over time. Despite this, their advantages outweigh their disad...
Main Authors: | Aaron Lerner, Carina Benzvi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/3/609 |
Similar Items
-
Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
by: Johann Stuby, et al.
Published: (2020-11-01) -
Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
by: Ming-Wei Kao, et al.
Published: (2023-04-01) -
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01) -
Pyoderma Gangrenosum Following Initiation of Immune Checkpoint Inhibitor Therapy
by: Macartney E Welborn, et al.
Published: (2018-10-01) -
Immune Checkpoint Inhibition in Pediatric Oncology Patients: A Single-Institution Experience
by: Natalia Wojciechowska, et al.
Published: (2024-03-01)